Pelthos Therapeutics Inc. (NYSEAMERICAN:PTHS – Get Free Report) Director Ezra Friedberg sold 558 shares of the firm’s stock in a transaction dated Thursday, July 2nd. The stock was sold at an average price of $26.09, for a total transaction of $14,558.22. Following the completion of the sale, the director directly owned 81,042 shares of the company’s stock, valued at approximately $2,114,385.78. This represents a 0.68% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Pelthos Therapeutics Stock Performance
Shares of NYSEAMERICAN PTHS traded up $0.27 during midday trading on Tuesday, hitting $24.60. 36,589 shares of the company traded hands, compared to its average volume of 15,341. Pelthos Therapeutics Inc. has a 12-month low of $16.09 and a 12-month high of $37.50. The company has a market capitalization of $85.61 million, a price-to-earnings ratio of -1.19 and a beta of 3.10. The firm has a 50-day moving average of $26.73. The company has a current ratio of 2.79, a quick ratio of 1.86 and a debt-to-equity ratio of 1.41.
Pelthos Therapeutics (NYSEAMERICAN:PTHS – Get Free Report) last issued its quarterly earnings data on Thursday, May 14th. The company reported ($3.09) EPS for the quarter. The business had revenue of $10.91 million for the quarter. As a group, equities analysts expect that Pelthos Therapeutics Inc. will post -12.63 earnings per share for the current year.
Hedge Funds Weigh In On Pelthos Therapeutics
Analyst Upgrades and Downgrades
PTHS has been the topic of several research reports. Cantor Fitzgerald began coverage on Pelthos Therapeutics in a research report on Wednesday, April 1st. They set an “overweight” rating and a $50.00 price target on the stock. Zacks Research upgraded Pelthos Therapeutics from a “strong sell” rating to a “hold” rating in a report on Tuesday, March 24th. HC Wainwright reissued a “buy” rating and set a $60.00 price objective on shares of Pelthos Therapeutics in a research report on Thursday, March 19th. Finally, Oppenheimer boosted their target price on shares of Pelthos Therapeutics from $62.00 to $66.00 and gave the company an “outperform” rating in a report on Friday, May 15th. Five investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $55.80.
Check Out Our Latest Report on PTHS
Pelthos Therapeutics Company Profile
We are a clinical-stage biotech company focused on developing and commercializing new therapeutics to alleviate pain. Our clinical focus is to selectively target the sodium ion-channel known as “NaV1.7”, as well as other receptors in the NaV family. NaV1.7 has been genetically validated as a pain receptor in human physiology. Genetic studies have shown that families with a certain inherited NaV1.7 modulation consistently show a pathology of not feeling pain. A NaV1.7 blocker is a chemical entity that modulates the structure of the sodium-channel in a way to prevent the transmission of pain perception to the central nervous system (“CNS”).
Featured Stories
- Five stocks we like better than Pelthos Therapeutics
- Apple and Broadcom Forge a Decade-Long Silicon Fortress
- SK Hynix’s Nasdaq Listing Could Reset the AI Memory Trade
- The AI Chip Sell-Off Looks Scary, But the Real Story May Be Liquidity
- Palantir’s CEO Just Called Out OpenAI and Anthropic
Receive News & Ratings for Pelthos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pelthos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
